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Abstract
Vaccines for counteracting inhibition of neutrophil degranulation by pathogenic cellular microorganisms
comprise one or more purines conjugated to antigenic carriers. The purines include adenine and/or guanine
in the form of a base, nucleoside, or nucleotide. The vaccines can be used with cattle to increase resistance to
infections by Brucella abortus (brucellosis) and/or Haemophilus somnus (thromboembolic
meningoencephalitis) and related symptomatic complex.
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[57] ABSTRACT 
Vaccines for counteracting inhibition of neutrophil 
degranulation by pathogenic cellular microorganisms 
comprise one or more purines conjugated to antigenic 
carriers. The purines include adenine and/ or guanine in 
the form of a base, nucleoside, or nucleotide. The vac 
cines can be used with cattle to increase resistance to 
infections by Brucella abortus (brucellosis) and/or Hae 
mophilus somnus (thromboembolic meningoencephali 
tis) and related symptomatic complex. 
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VACCINES FOR COUNTERACTING INHIBITION 
OF NEUTROPHIL DEGRANULATION 
FIELD OF INVENTION, BACKGROUND, AND 
PRIOR ART 
The ?eld of the invention is vaccines for preventing 
or reducing the severity of infectious diseases. More 
particularly, the invention is concerned with vaccines 
against pathogenic microorganisms which resist neutro 
phil destruction by inhibiting degranulation. 
The mechanisms by which bacteria resist phagocytic 
destruction have been summarized by Densen and Man 
del: “Reviews of Infectious Diseases,” Vol. 2, No. 5, 
Sept.-Oct. 1980, pages 817-838. Relevant here is the 
phagocytosis sequence in which polymorphonuclear 
neutrophils (PMNs) ingest invading bacteria and the 
PMNs granules move toward and merge with the 
phagosome containing the ingested microorganisms, 
releasing enzymes which assist in the destruction of the 
bacteria. If degranulation is inhibited or does not occur 
at all, ingested microorganisms may be able to survive 
within the PMNs. In Table 1 (page 821), Densen and 
Mandel list some pathogens which have been reported 
to inhibit degranulation, including Mycobacterial spe 
cies M. tuberculosis, M. micron‘, and M. bovis. and also 
T oxoplasma gondii. It appears, however, that prior re 
ports have related to ?xed macrophages in the tissues 
rather than circulating PMNs. 
Prior to the experimental work leading to the present 
invention, the mechanisms by which certain microor 
ganisms inhibit degranulation of PMNs is not known to 
have been elucidated. In macrophages, cyclic AMP 
(cAMP), a well-known cell regulator, was reported to 
play a role in the inhibition of macrophage degranula 
tion by Mycobacteria. See Lowrie et al. (1975), Nature, 
254:600-602; and Lowrie et al. (1979), J. Gen. Mi 
crobioL, 110:431-441. These researchers found that mac 
rophages ingesting live mycobacteria had increased 
concentrations of intracellular cyclic AMP. It was sug 
gested that at least part of the cAMP may have been 
produced by the bacteria but this speculation was not 
con?rmed. Cyclic AMP as well as cyclic GMP 
(cGMP) are known to be important intracellular regula 
tory molecules. In general, increased intracellular 
cAMP tends to inhibit cell functions while increased 
cGMP enhances cell functions. 
The regulation of macrophage lysosomal secretion by 
adenosine and related compounds has recently been 
reported: Riches, et al. (1985), J. Leukocyte Biol., 
37:545-557. Riches et al. found that zymosan particle 
stimulated beta-galactosidase secretion by mouse peri 
toneal macrophages could be inhibited by adenosine, 
AMP, and related compounds, as well as guanosine. 
SUMMARY OF INVENTION 
Polymorphonuclear neutrophils (PMNs) comprise a 
major cellular defense mechanism for protecting ani-’ 
mals from infection by cellular organisms (bacteria, 
fungi, etc.). In the experimental work leading to this 
invention, bacterial infections of cattle which are not 
killed effectively by neutrophils were studied. One of 
these pathogens is Brucella abortus, which is the causa 
tive agent of bovine brucellosis. Another is Haemoph 
ilus somnus, which causes several disease syndromes in 
cattle, including thromboembolic meningoencephalitis, 
and a symptomatic complex of respiratory infection, 
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septicemia, and thrombosis. Both microorganisms were 
studied. 
It was found that B. abortus and H. somnus both pro 
duce factors which inhibit degranulation of PMNs, and 
that neutrophil ingestion of these bacteria does not re 
sult in the usual process of neutrophil phagocytosis. 
Surprisingly, after extensive laboratory work, the inhib 
iting factors were identi?ed as purines, both pathogens 
liberating adenine and GMP. Guanine was also detected 
for H. somnus. Even more surprisingly, it was found 
that these purines in pure form are capable of inhibiting 
degranulation of PMNs. The conclusion indicated is 
that neutrophil degranulation is depressed and may be 
totally inhibited by certain adenine or guanine contain 
ing water-soluble purines. 
These discoveries have led to a vaccine for counter 
acting inhibition of neutrophil degranulation. The vac 
cine comprises a parenteral]y-administrable sterile aque 
ous solution of one or more purines conjugated to anti 
genic proteins. The protein conjugated to purines may 
contain adenine or guanine as a base, nucleoside or 
nucleotide. The conjugated purines are capable of gen 
erating antibodies which are speci?c to each purine 
type (viz. adenine or guanine types). Antisera to adeno 
sine, for example, is reactive with adenine, adenosine, 
and AMP. Similarly, antisera to guanosine is reactive 
with guanine, guanosine, and GP. However, adenosine 
induced antisera has little cross-reaction with guanine 
and related purines. Similarly, guanosine antisera does 
not appreciably react with adenine compounds. 
In a preferred embodiment, the vaccine contains each 
of the two kinds of purines conjugated to antigenic 
proteins. For example, the vaccine preferably contains 
adenosine and guanosine in nucleoside form. The anti 
bodies generated by this combination vaccine are reac 
tive with both types of purines. 
Degranulation inhibitors produced by bacteria such 
as B. abortus and H. somnus are visualized as concen 
trated in the cell envelopes, and particularly on their 
outer surfaces. In a postulated mechanism, the vacci 
nated animals produce antipurine antibodies which bind 
to the purines on the outer surfaces of the bacterial cells 
prior to their ingestion by PMNs. The degranulation 
inhibitory action of the bacterial purines is thereby neu 
tralized. Ingestion of the bacteria by the PMNs can then 
result in the usual process of destruction by neutrophil 
degranulation and related mechanisms. 
DETAILED DISCLOSURE 
Purines for use in preparing vaccines of this invention 
are available commercially. One or more of the follow 
ing purines should be employed: 
Adenine Type Guanine Type 
adenine guanine 
adenosine guanosine 
2'-deoxyadenosine 2'-deoxyguanosine 
AMP GMP 
dAMP dGMP 
Adenine and guanine are referred to as bases, while 
adenosine, 2'-deoxyadenosine, guanosine, and 2'-deox 
yguanosine are nucleosides. AMP (adenosine 5'-phos 
phate), dAMP (deoxyadenosine 5'-phosphate), GMP 
(guanosine 5’-phosphate) and dGMP (deoxyguanosine 
5’-phosphate) are nucleotides. For the purposes of this 
invention, the purines may be in the form of bases, nu 
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cleosides or nucleotides. However, the use of adenosine 
and guanosine in nucleoside form is believed to produce 
the most effective antisera and is therefore preferred. 
For use in the vaccine, the purines are attached to 
proteins having antigenic properties. The protein “car 
riers” for the purines enhance the production of anti 
bodies to the purines. The protein may comprise animal 
or human serum albumin, keyhole limpet hemocyanin, 
tetanus toxoid, ovalbumin, etc. 
Purines may be conjugated to the carrier proteins 
using carbodiimide coupling as described by Halloran et 
al. (1966), J. Immunology, 96:373-378. Ribonucleosides 
and ribonucleotides such as adenosine, guanosine, AMP 
dAMP, GMP and dGMP may be conjugated to prote 
ins by the periodate reaction procedure of Erlanger et 
al. (1964), Pro. Natl. Acaa’. Sci. U.S.A., 52:68-74. See, 
also, Butler et al. (1962), Pro. Natl. Acad. Sci. U.S.A., 
48:1597-1602. As reported by Erlanger and co-workers, 
purines and pyrimidines conjugated to antigenic prote 
ins are capable of generating purine or pyrimidine spe 
ci?c antibodies. 
The conjugated purines are water-soluble, and can 
therefore be dissolved in water for vaccine use. For 
example, the aqueous carrier may comprise normal 
saline. The concentration of the aqueous solution is not 
critical. For example, the concentrations may range 
from about 0.25 to 5.0 milligrams of protein conjugate 
per milliliter of solution. Where more than one protein 
conjugate is present, such as mixed conjugates of adeno~ 
sine and guanosine, each of the conjugates may be pres 
ent in concentrations of from about 0.1 to 2.5 milligrams 
per milliliter. A typical antibody producing dose for 
large domestic animals is from about 0.5 to 10.0 milli 
grams of each type of conjugate per dose. For example, 
if the vaccine comprises a mixture of protein conjugates 
of both adenosine and guanosine, as preferred, each of 
the types of conjugates will be used in the speci?ed dose 
amounts. 
Although not essential, if desired an adjuvant may be 
included in the vaccine. For example, suitable adjuvants 
are: (l) Freund’s incomplete adjuvant which is emulsi 
?ed with an equal volume of the aqueous purine con 
taining vaccine and administered in 2 ml doses subcuta 
neously; or (2) a 0.2% solution of alum which had ad 
sorbed the purine containing vaccine and is adminis 
tered in 2 ml closes subcutaneously. 
The vaccine should be prepared under sterile condi 
tions so that the solutions are sterile, and the solutions 
should be aseptically packaged. Packaging in vials can 
involve sterilization either before or after packaging. 
The vials may contain one or more doses, and may be 
provided with a closure pierceable by a hypodermic 
needle. The vaccine for cattle may be packaged as a 
sterile solution in multidose dark-glass vials containing 
10 doses (20 ml), 25 doses (50 ml) or 50 doses (100 ml). 
The vials may be sealed with a closure pierceable by a 
hypodermic needle and would be appropriately labeled. 
The vaccines of this invention are generally suitable 
for use in counteracting inhibition of neutrophil degran 
ulation by pathogenic cellular microorganisms. The 
vaccines are designed for increasing resistance to patho 
genic cellular microorganisms which liberate purines as 
a defense to neutrophils. The vaccines are administered 
to the animals subject to the infection, and a sufficient 
amount of the conjugated purines are given to generate 
antibodies to adenine and/or guanine. Preferably, as 
described above, the vaccine is formulated and adminis 
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tered to generate antibodies to both adenine and gua 
nine-type purines. 
The vaccines of this invention are believed to be 
particularly effective in improving the resistance of 
cattle to B. abortus and H. somnus. It will be apparent, 
however, that the vaccines of this invention have wider 
applicability, and can be used to increase the resistance 
of cattle and other animals to infections by bacteria, 
fungi and yeasts, which have developed a defense 
mechanism against neutrophils involving the liberation 
of adenine and/or guanine-type purines. The vaccines 
of this invention are particularly advantageous for use 
with domestic animals, including cattle, swine, sheep, 
horses, and poultry. However, it is believed that they 
will also have applications in human preventive medi 
cine. Speci?c diseases of domestic animals caused by 
microorganisms which resist destruction by neutrophils 
and which may be prevented by the vaccines include: 
Salmonellosis, Listeriosis, Tuberculosis, Histoplasmo 
sis, and Blastomycosis (all of which occur in many do 
mestic species), and Rhodococcus equi infection of foals, 
Bordetella bronchiseptica of swine, and Paratuberculosis 
in cattle. 
The vaccines are administered parenterally. The pre 
ferred route is subcutaneous (S.C.) but other routes can 
be used, including intramuscular (I M.) and intravenous 
(I.V.). 
The scienti?c and practical aspects of the present 
invention are further illustrated by the following exam 
ples. 
EXAMPLE I 
A vaccine for immunization of cattle against B. abor 
tus and/or H. somnus can be prepared as follows. The 
vaccine will contain guanosine and adenosine linked to 
keyhole limpet hemocyanin (KLH), using the proce 
dure of Erlanger and Beiser. See Butler et al. (1962), 
Proc. Natl. Acad. Sci. USA 48:1597-1602. The guanosine 
or adenosine (100 mg) is dissolved in 5.0 ml of 0.1 M 
NaIO4 and allowed to stand 20 minutes at room temper 
ature. Excess NaIO4 is decomposed by the addition of 
0.3 ml 1.0 M ethylene glycol followed by a 5-minute 
period at room temperature. The reaction mixture is 
then added to an aqueous solution (10 ml) of 280 mg 
KLH which had been adjusted to pH 9-9.5 with 5% 
potassium carbonate. Stirring is continued for 45 min 
utes, the pH being maintained at 9—9.5 with 5% potas 
sium carbonate. A solution of 150 mg of NaBH4 in 10 ml 
H2O is then added, followed one hour later by adjust 
ment of the pH to 8.5 using 1 M NH4OH. The solution 
is then dialyzed, lyophilized, and rehydrated in saline to 
a concentration of 2.0 mg of protein per ml. The guano 
sine and adenosine conjugates are then mixed together 
into one solution. 
The alum adjuvanted vaccine is prepared by adding 
2.33 ml of 10 percent AlCl3 to 50 ml of the adenosine 
guanosine conjugate mixture then adding suf?cient 20 
percent NaOl-I to bring the reaction to pH 7.0. The 
solution is then diluted to 100 ml with saline to produce 
a vaccine containing 1.0 mg of protein (conjugated to 
adenosine and guanosine) per m1 adsorbed to alum 
which serves as the adjuvant. The vaccine is prepared 
aseptically from sterile ingredients, or it can be steril 
ized by irradiation and aseptically packaged as a sterile 
solution in multidose glass vials containing 20 ml, 50 ml, 
or 100 ml of vaccine. The vials can be sealed with a 
closure pierceable by a hypodermic needle and would 
be appropriately labeled. Cattle are immunized with 
4,701,323 
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two 2.0 ml doses of vaccine administered subcutane 
ously 2 weeks apart. 
EXAMPLE II 
The preparation of guanosine monophosphate 
(GMP) antigen suitable for production of anti-nucleo 
tide antibodies in rabbits was accomplished using a 
modi?cation of the procedures of Halloran and Parker 
(1966), J. Immunol. 96:373. All chemicals used in this 
work were purchased from Sigma Chemical Co., St. 
Louis Brie?y, 10.0 mg of GMP was mixed with 4.0 mg 
of either human serum albumin (HSA) or keyhole lim 
pet hemocyanin (KLH) in 1.0 ml of tissue culture grade 
water. The pH of the solution was adjusted to 7.5 and 10 
mg of l-ethyl-3-diisopropylaminocarbodiimide-HC] 
(EDC) as added to the reaction mixture. The solution 
was incubated for 24 hrs. at room temperature in the 
dark. Following incubation, the reaction mixture was 
dialyzed at 4" C. against 0.01 M Tris chloride, pH 7.6, 
for 18 hrs. The dialyzed solution was then evaluated by 
scanning U.V. spectrophotometry to con?rm coupling. 
The solution was then restored to isotonicity with the 
addition of 10X phosphate buffered saline. 
Four rabbits were used for the production of speci?c 
antisera. Each rabbit received one of four antigen 
preparatiorzs in two 250 pl (protein dry wt.) doses 
spaced two weeks apart as follows: 
(1) GMP-HSA, IV 
(2) GMP-HSA, IM with Freund’s incomplete adju 
vant 
(3) GMP-KLH, IV 
(4) GMP-KLH, IM with Freund’s incomplete adju 
vant. 
Following the second and fourth weeks, serum samples 
were collected and evaluated by an ELISA procedure 
to detect speci?c anti-nucleotide antibody. 
The ELISA plates were set up such that the sera 
raised against HSA-coupled GMP were evaluated 
against KLH-coupled GMP while the sera raised 
against KLH-coupled GMP were evaluated against 
HSA-coupled GMP. This system allowed detection of 
antibody molecules directed against the nucleotide hap 
ten. The rabbit which received GMP-KLH, IV, pro 
duced anti-GMP antibody with a maximum titler of 
1:512 (OD=0.524). 
EXAMPLE III 
1. Preparation of Immunogen. 
Guanosine-KLH, GMP-KLH, and GMP-BSA were 
pepared by the method of Erlanger and Beiser (Proc. 
Natl. Acad. Sci. USA 48:1597, 1962). 
2. Immunization of rabbits with GMP-BSA. 
A total of 3 rabbits were used. The procedure for 
immunization with GMP-BSA (without adjuvant) is 
shown in the following table. 
Day Treatment 
0 2 mg GMP-BSA in PBS; S.C. 
7 2 mg GMP-BSA in PBS; I.V. 
l4 2 mg GMP-BSA in PBS; I.V. 
21 lst bleeding 
27 2 mg GMP-BSA in PBS 
34 2nd bleeding 
41 2 mg GMP-BSA in PBS; I.V. 
48 3rd bleeding 
62 2 mg GMP-BSA in PBS; I.V. 
69 4th bleeding 
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3. Anti-GMP response in rabbits. 
The antibody titer was detected by ELISA using 
GMP-KLH as the antigen. The table below shows the 
anti-GMP antibody titers of the three rabbits: 
Rabbit #1 Rabbit #2 Rabbit #3 
181 bleeding 1:1280 1:320 1:640 
2nd bleeding 1:5120 1:320 1:640 
3rd bleeding 1:5120 1:320 1:640 
4th bleeding 1:5120 1:320 1:1280 
4. Immunization of Calves with GMP-KLH. 
Day Treatment 
0 1 mg GMP-KLH or guanosine-KLH in FlA; S.C 
7 1 mg GMP-KLH or guanosine-KLl-l in FIA; S.C 
1st bleeding 
l4 1 mg GMP-KLH or guanosine-KLH in FIA; S.C 
2nd bleeding 
5. Anti-GMP response in calves. 
The antibody titer was determined using an enzyme 
linked immunosorbent assay (ELISA) with GMP-BSA 
bound to the ELISA plate as the test antigen. 
Calf #1 Calf #2 
1st bleeding 1:320 1:160 
2nd bleeding 1:20.480 l:l0,240 
6. Anti-guanosine response in calves. 
The antibody titer was determined using an ELISA 
with guanosine-BSA bound to the ELISA plate as the 
antigen. 
Calf #3 Calf #4 
1st bleeding 1:200 1:100 
2nd bleeding 126,400 1:1,600 
7. Cross reactivity of the anti-guanosine antibody. 
The presence of free guanine, guanosine, (1 guanosine, 
GMP and dGMP in the ELISA assay strongly inhibited 
the binding of antiguanosine antibody to the guanosine 
BSA bound to the plate. Thus indicating that antibody 
directed against guanosine will also bind to each of 
these other guanine-containing molecules. The presence 
of free adenine, adenosine, or AMP in the ELISA assay 
did not inhibit binding of anti-guanosine antibody to 
guanosine, therefore, indicating that anti-guanosine 
antibody does not cross-react with these adenine-con 
taining molecules. 
8. Cross reactivity of the bovine anti-GMP antibody. 
The presence of free GMP, dGMP, and AMP in the 
ELISA assay strongly inhibited the binding of anti 
GMP antibody to GMP, indicating that antibody to 
GMP will also bind to each of these molecules. The 
presence of free guanine, guanosine, and d guanosine in 
the ELISA assay only weakly inhibited the binding of 
anti-GMP antibody to GMP. The presence of free ade 
nine or adenosine in the ELISA assay did not inhibit the 
_binding of anti-GMP antibody to GMP. These observa 
tions indicate that the ribose phosphate portion of GMP 
is immunodominant and that much of the antibody 
formed is against this portion of the molecule. This 
would explain why the anti-GmP serum binds more 
strongly to AMP than to guanine and guanosine. 
4,701,323 
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9. Abbreviations: 
GMP = Guanosine monophosphate 
BSA =Bovine serum albumin 
KLH = Keyhole limpet hemocyanin 
FlA=Freund’s incomplete ad juvant 
PBS = phosphate buffered saline 
S.C. = subcutaneously 
I.V. = Intravenously 
EXAMPLE IV 
Two components responsible for the inhibition of 
bovine neutrophil degranulation were extracted from 
the bacteria by gentle heating. The inhibitory compo 
nents were isolated by membrane ?ltration and reverse 
phase high performance liquid chromatography and 
designated as fractions 3b and 10. Preliminary charac 
terization and identi?cation of the molecules were ac 
complished through both physical and chemical analy 
ses. The results of these studies indicated that neither 
fraction 3b nor 10 contained detectable proteins or lip 
ids. Fraction 3b contained a small amount of carbohy 
drate while fraction 10 did not contain a detectable 
amount. Both fractions exhibited maximum absorbence 
of ultraviolet light at 260n.m and had molecular weights 
of less than 1,000 daltons. These results are consistent 
with the properties of nucleotide or nucleotide-like 
molecules. Fractions 3b and 10 were analyzed by re 
verse phase high performance liquid chromatography 
and thin layer chromatography and compared with 
nucleotide and base standards. These investigations 
indicated the fraction 3b co-eluted and co-migrated 
with 5'-guanosine monophosphate while fraction 10 
co-eluted and co¢migrated with adenine. The biological 
effects of 5’-guanosine monophosphate, adenine, and B. 
abortus fractions 3b and 10 on bovine neutrophil func 
tions were determined. None of the compounds affected 
the ability of neutrophils to ingest bacteria or produce 
superoxide anion in response to ingestion. Iodination 
activity of neutrophils (a measure of myeloperoxidase 
HgOg-halide activity) was inhibited to approximately 
65% of control by similar concentrations of 5’-guano 
sine monophosphate and fraction 3b. Iodination was 
also suppressed to approximately 80% of control by 
similar concentrations of adenine and fraction 10. These 
results indicate that B. abortus fractions 3b and 10 are 
5'-guanosine monophosphate and adenine, respectively, 
and it is these materials which are at least in part respon 
sible for the survival of the bacteria within bovine neu 
trophils. 
EXAMPLE V 
H. somnus fractions which are inhibitory to degranu 
lation by bovine PMNs were isolated by the following 
procedures: A washed suspension of H. samnus in PBS 
was either heat-extracted at 60° C: for 1 hour or incu 
bated at 37° C. for 2 hours followed by centrifugation. 
The supernatant was collected and ?ltered through an 
ultra?ltration membrane with a molecular weight 
(MW) cutoff of 300,000 daltons and then through an 
other membrane with MW cutoff of 1,000 daltons. The 
?nal ?ltrate was termed HElF-60 for the fraction iso 
lated by heat extraction at 60° C. and HElF-37 for the 
fraction isolated by incubation at 37° C. 
Preliminary chemical characterization indicated that 
both fractions contained components that were chemi 
cally and physically similar to nucleotides or nucleo 
tide-like compounds. Consequently, the components 
present in each fraction were separated by using a high 
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performance liquid chromatography system equipped 
with a C-l8 reverse-phase column under the chromato 
graphic conditions which were previously described for 
separation of nucleotides or nucleotide-like compounds 
from bacterial cells (S.M. Payne and B.N. Ames, Anal. 
Biochem. 1982, 123: 151-161). 
The components present in each fraction were identi 
?ed by the following procedures which were described 
elsewhere (R. A. Harwick et al., 1979, J. Chromatog., 
168:659-676). 
1. Retention time-Commercially available standards 
with a similar retention time to an unknown peak were 
co-injected with the fraction and changes in peak shape 
noted. Standards which caused an unknown peak to 
increase in height without the appearance of a shoulder 
or unusual peak broadening were considered to have 
the same retention time as the unknown peak. Accord 
ingly, the components present in HElF-60 were tenta 
tively identi?ed as cytosine, uracil, guanine, guanosine, 
adenine, CMP, UMP, GMP, AMP, CDP, GDP, and 
ADP. HElF-37 contained the same components but in 
different quantities. The presence of cytosine, uracil, 
guanine, guanosine, and adenine was further con?rmed 
by using the same technique but under different chro 
matographic conditions which were described for the 
identi?cation of nucleosides, bases and other UV 
absorbing, low-molecular weight compounds (K. 
Nakano et al. 1982, J. Chromatog. 233:51-60). 
2. Enzymatic treatments—The presence of ribonucle 
otides and guanine in each fraction was further con 
?rmed by treating each fraction with 5’-nucleotidase 
and guanase, respectively. Treatment with 5’-nucleoti 
dase converted all ribonucleotides into their corre 
sponding ribonucleosides, whereas treatment with gua 
nase caused the appearance of a peak co-eluting with 
xanthine. 
When all the identi?ed compounds were titrated for 
their effect on degranulation by bovine PMNs, most of 
them, except cytosine and CDP, were found to be inhib 
itory. The inhibition caused by these compounds was 
dose-dependent. When the concentrations of the com 
ponents in each fraction were estimated, it was found 
that guanine and adenine had concentrations high 
enough to cause most of the suppressive activity ob 
served for HElF-37, whereas guanine and GMP were 
the major suppressive components in HElF-60. 
We claim: ' 
1. A vaccine for counteracting inhibition of neutro 
phil degranulation by pathogenic cellular microorgan 
isms, comprising an aseptically-packaged, parenterally 
administrable sterile aqueous solution of at least one 
purine conjugated to an antigenic protein, each of said 
conjugated purines containing adenine or guanine as a 
base, nucleoside, or nucleotide thereof, the amount of 
said conjugated purine in said packaged vaccine provid 
ing single or multiple vaccine doses effective for gener 
ating antibodies to adenine and/or guanine. 
2. The vaccine of claim 1 in which said conjugated 
purine at least contains adenine as a base, nucleoside, or 
nucleotide. 
3. The vaccine of claim 1 in which said conjugated 
purine at least contains adenine in a form selected from 
adenine, adenosine, 2'-deoxyadenosine, AMP and 
dAMP. 
4. The vaccine of claim 1 in which said conjugated 
purine at least contains guanine as a base, nucleoside, or 
nucleotide. 
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5. The vaccine of claim 1 in which said conjugated 
purine at least contains guanine in a form selected from 
guanine, guanosine, 2'-deoxyguanosine, GMP, and 
dGMP. 
6. The vaccine of claim 1 which contains protein 
conjugated adenosine in admixture with protein conju 
gated guanosine. 
7. A vaccine for counteracting inhibition of neutro 
phil degranulation by pathogenic microorganisms, com 
prising an aseptically-packaged, parenterally-admini 
strable sterile aqueous solution of a mixture of at least 
two kinds of purines conjugated to antigenic protein, 
one of said kinds of conjugated purine containing ade 
nine and the other kind containing guanine, said purines 
being present in the form of bases, nucleosides, or nucle 
otides, the amount of each of said kinds of conjugated 
purines in said packaged vaccine providing single or 
multiple vaccine doses effective for generating antibod 
ies to both adenine and guanine. 
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8. The vaccine of claim 7 in which said one kind of 20 
conjugated purine contains adenine in a form selected 
from adenine, adenosine, and 2’-deoxyadenosine, AMP, 
and dAMP, and said other conjugated purine contains 
guanine in a form selected from guanine, guanosine, 
2’-deoxyguanosine, GMP, and dGMP. 
9. The method of increasing the resistance of domes 
tic animals to pathogenic cellular microorganisms 
which liberate purines as a defense against polymorpho 
nuclear neutrophils, comprising parenterally adminis 
tering to the animals subject to infection by the micro 
organism at least one vaccine dose of a sterile aqueous 
solution of at least one purine conjugated to an anti 
genic protein, said conjugated purine containing ade 
nine or guanine as a base, nucleoside or nucleotide 
thereof, the amount of said conjugated purine adminis 
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tered being effective to generate antibodies to adenine 
and/or guanine. 
10. The method of claim 9 in which said animals are 
selected from cattle, swine, sheep, horses, and poultry. 
11. The method of claim 9 or claim 10 in which at 
least one of said conjugated purines contains adenosine. 
12. The method of claim 9 or claim 10 in which at 
least one of said conjugated purines contains guanosine. 
13. The method of claim 9 or claim 10 in which said 
vaccine comprises a mixture of adenosine and guanosine 
conjugated to antigenic protein. 
14. The method of increasing the resistance of domes 
tic animals to pathogenic cellular microorganisms 
which liberate purines as a defense against polymorpho 
nuclear neutrophils, comprising parenterally adminis 
tering to animals subject to infection by the microorgan 
ism at least one vaccine dose of a sterile aqueous solu 
tion of a mixture of at least two types of purines conju 
gated to antigenic protein, one of said types of conju 
gated purines containing adenine and the other type 
containing guanine, said purines being present in the 
form of bases, nucleosides, or nucleotides, the amount 
of each of said kinds of conjugated purines in said vac 
cine dose being effective for generating antibodies to 
both types of said purines. 
15. The method of claim 14 in which said one conju 
gated purine contains adenosine and said other conju 
gated purine contains guanosine. 
16. The method of claim 9 or claim 14in which said 
animals are cattle and said microorganism is Bruce/la 
abartus. 
17. The method of claim 9 or claim 14 in which said 
animals are cattle and said microorganism is Haemoph 
ilus somnus. 
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